Psoriasis
61 programs · 60 companies
Programs
61
Companies
60
Trials
59
MOAs
40
SOS1iFXIaiIL-13iCDK4/6iKRASG12CiSTINGagMALT1iCD47iEZH2iBTKi
Drugs
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Terarelsin | Preclinical | SOS1 | ||
| AZN-1715 | Phase 3 | AHR | ||
| BMY-4586 | Preclinical | KRASG12C | ||
| Adagracapivasertib | NDA/BLA | BET | ||
| BMR-9762 | Phase 3 | Aβ | ||
| INC-5849 | Phase 2 | PCSK9 | ||
| Gelisertib | Approved | IL-23 | ||
| Zenorelsin | NDA/BLA | JAK2 | ||
| NMR-223 | NDA/BLA | C5 | ||
| Datocilimab | Phase 1 | TYK2 | ||
| RPT-8672 | Phase 2 | DLL3 | ||
| SLD-2973 | NDA/BLA | KIF18A | ||
| Mavucagene | Preclinical | C5 | ||
| CIP-2846 | Phase 3 | MALT1 | ||
| Bemainavolisib | Preclinical | KRASG12C | ||
| Tirabrutinib | Approved | CD3 | ||
| Doxaosocimab | Phase 1/2 | CGRP | ||
| DUK-IIT-810 | Phase 1/2 | PD-1 | ||
| Polatinib | Phase 1 | PARP | ||
| HOR-3482 | Phase 3 | MET | ||
| CGE-9788 | Phase 3 | APOC3 | ||
| ASM-5108 | Phase 1 | TYK2 | ||
| SAV-5205 | NDA/BLA | BTK | ||
| GYR-4594 | Preclinical | PLK4 | ||
| UNC-3197 | NDA/BLA | CD19 | ||
| Datolucimab | Phase 1/2 | Tau | ||
| Fixainavolisib | Phase 2/3 | APOC3 | ||
| TUR-4034 | Phase 2/3 | C5 | ||
| Adagrazasiran | Approved | CD3 | ||
| GAL-555 | Phase 3 | C5 | ||
| Tiranaritide | Preclinical | FLT3 | ||
| Zoriosocimab | Phase 2 | HER2 | ||
| RLY-2544 | Preclinical | FLT3 | ||
| Lirainavolisib | Preclinical | TIGIT | ||
| Nirasertib | Phase 2 | CD20 | ||
| Zorirelsin | Phase 3 | CDK2 | ||
| CHR-2584 | Phase 2 | TYK2 | ||
| MAS-IIT-445 | NDA/BLA | BTK | ||
| DUK-IIT-613 | Approved | WRN | ||
| DCP-2468 | Preclinical | MALT1 | ||
| CAT-8632 | Phase 2/3 | IL-13 | ||
| CYM-2446 | Phase 2/3 | MET | ||
| Fixatuximab | Phase 3 | GPRC5D | ||
| Polatinib | Preclinical | PLK4 | ||
| Nidalemzoparlimab | Phase 1 | SOS1 | ||
| NOI-4498 | Phase 1 | Cl18.2 | ||
| Nidacilimab | Approved | JAK2 | ||
| GLO-6047 | Preclinical | CD47 | ||
| 618-5050 | Phase 2 | IL-17A | ||
| Fixasacituzumab | NDA/BLA | CD123 | ||
| VAL-4454 | Preclinical | Aβ | ||
| Datofotisoran | Phase 1/2 | C5 | ||
| 654-1692 | Phase 2 | DLL3 | ||
| Capimavacamten | Phase 1 | TIGIT | ||
| XER-568 | Phase 1 | Aβ | ||
| Olpaglumide | Approved | KRASG12C | ||
| NAT-IIT-714 | Phase 3 | BET | ||
| WST-3903 | Preclinical | FXIa | ||
| Talatuximab | Phase 2 | AuroraA | ||
| CRD-4273 | Phase 1/2 | KIF18A | ||
| DNA-3921 | NDA/BLA | AHR |
Trials (59)
| NCT | Drug | Phase | Status |
|---|---|---|---|
| NCT05621676 | Terarelsin | Preclinical | Not yet recr... |
| NCT06248243 | Terarelsin | Preclinical | Terminated |
| NCT07200293 | AZN-1715 | Phase 3 | Recruiting |
| NCT06766578 | AZN-1715 | Phase 3 | Not yet recr... |
| NCT03097479 | BMR-9762 | Phase 3 | Terminated |
| NCT03227659 | BMR-9762 | Phase 3 | Not yet recr... |
| NCT04688187 | BMR-9762 | Phase 3 | Active |
| NCT08565171 | BMR-9762 | Phase 3 | Recruiting |
| NCT05119603 | INC-5849 | Phase 2 | Active |
| NCT07931894 | Gelisertib | Approved | Recruiting |
| NCT03078208 | Gelisertib | Approved | Terminated |
| NCT04491307 | Gelisertib | Approved | Recruiting |
| NCT06235307 | Zenorelsin | NDA/BLA | Completed |
| NCT04743209 | NMR-223 | NDA/BLA | Terminated |
| NCT08451994 | Datocilimab | Phase 1 | Terminated |
| NCT06675278 | RPT-8672 | Phase 2 | Not yet recr... |
| NCT08816147 | Mavucagene | Preclinical | Terminated |
| NCT03357238 | CIP-2846 | Phase 3 | Not yet recr... |
| NCT06001933 | Bemainavolisib | Preclinical | Active |
| NCT07684923 | Tirabrutinib | Approved | Not yet recr... |